$GH

Eltoukhy Helmy sold $12.6M of GH (indirect holdings)

Eltoukhy Helmy (Co-Chief Executive Officer) sold 100,000 indirectly-held shares of Guardant Health, Inc. (GH) at an average of $126.30 ($125.57–$132.55, $12.63M total) across 7 trades on 2026-06-05.

Original reporting
SEC EDGAR · Eltoukhy Helmy
Published Jun 8, 2026, 10:29 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 8, 2026, 10:32 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

Helmy’s open-market sale reduces insider exposure and can slightly pressure sentiment, but it does not provide new operational/financial information about Guardant Health.

02

Market read

Traders may treat the disclosure as a minor sentiment datapoint rather than a catalyst.

03

What to watch

Check whether other insiders or large holders also sold/bought around the same window; single-officer sales can be idiosyncratic.

Relevance 7/10Novelty 6/10Timing: filed June 8; trades executed June 5

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for Guardant Health.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health co-CEO Eltoukhy Helmy sold about $12.63M of GH shares via an open-market sale across 7 trades (Form 4).

Expected impact

Likely limited near-term impact; any effect is more sentiment/positioning than fundamentals.

Evidence & confidence

The filing discloses transaction size and timing, but insider sales alone rarely drive sustained repricing without linkage to new company events.

Market effects

No direct sector read-through; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sale may be planned for liquidity/tax needs; absence of a stated 10b5-1 plan doesn’t automatically imply bearish fundamentals.

Key entities

  • Guardant Health, Inc.

    Company whose shares were sold by an officer/director insider.

  • Eltoukhy Helmy

    Co-Chief Executive Officer and director who executed the sale.

Related articles

$GHHighAI 9/10

Guardant Health (GH) Q2 2026 Earnings Call Transcript

Guardant Health (GH) reported Q2 2026 revenue of $335 million, up 44% year over year, driven by Oncology, Biopharma & Data, and Screening. Oncology revenue was $219.1 million, up 38%, with test volumes around 104,000. Full-year guidance: revenue $1.34 to $1.36 billion and free cash flow burn $195 to $205 million.

$GHMedAI 8/10

New blood test to detect colon cancer clears FDA approval

The FDA approved Freenome’s SimpleScreen blood test for colorectal cancer screening in adults aged 45+ at average risk. In a study of 48,000+ people, it detected about 80% of colorectal cancers and correctly tested negative in about 90% without cancer or advanced precancer. It is expected to launch this fall with Abbott. Guardant Health’s Shield was approved in 2024.

$GHMedAI 8/10

Guardant Health, Inc. Q2 2026 Earnings Call Summary

Guardant Health reported 44% YoY Q2 2026 revenue growth, citing strong Oncology and Screening performance. It raised full-year 2026 revenue guidance to $1.34B-$1.36B and expects lower Shield cost per test. FDA approval of Guardant360 Liquid CDx and UnitedHealth coverage for Shield from Aug. 1, 2026 are key catalysts.

$GHHighAI 9/10

Why is Guardant Health stock surging today?

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade Investing.com -- Guardant Health stock surged 8.8% in after-hours trading after the Palo Alto-based liquid biopsy pioneer reported second-quarter 2026 results that significantly exceeded revenue expectations, with sales reaching $335 million — a 44% year-over-year increase that beat the Wall Street consensus of roughly $314 million by approximately 6.4%.